National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 67360-67361 [2020-23368]
Download as PDF
<![CDATA[
67360
Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices
Dated: October 19, 2020.
Brian R. Berridge,
Associate Director, National Toxicology
Program.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2020–23444 Filed 10–21–20; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Prospective Grant of an Exclusive
Patent License: Development of a
Direct Ocular Administered
Formulation of Metformin for Use in
Therapeutic Treatment of Retinal
Degenerative Diseases in Humans
National Institutes of Health
AGENCY:
National Institutes of Health
BILLING CODE 4140–01–P
National Institutes of Health,
HHS.
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Emergency Awards: Rapid
Investigation of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS–CoV–2) and
Coronavirus Disease 2019 (COVID–19).
Date: November 20, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G41,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Tara Capece Scientific
Review Officer, Scientific Review Program,
Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers
Lane, Room 3G41, Rockville, MD 20852
,240–191–4281, capecet2@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 16, 2020.
Tyeshia M. Roberson,
Program Analyst. Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–23373 Filed 10–21–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
17:35 Oct 21, 2020
Jkt 253001
ACTION:
Notice.
The National Eye Institute, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice certain of the inventions
embodied in the Patents and Patent
Applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice to Connectyx Technologies
Holdings Group located in Boca Raton,
Florida.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before November 6, 2020 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Tedd Fenn, Senior
Technology Transfer Manager, NCI
Technology Transfer Center at
Telephone: (240) 276–5530 or Email:
Tedd.Fenn@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
U.S. provisional patent application
No. 62/899,899 and entitled, ‘‘Druggable
Targets to Treat Retinal Degeneration’’
filed September 13, 2019 (E–227–2017–
US–01); International Patent
Application No.: PCT/US2020/050540
and entitled, ‘‘Druggable Targets to
Treat Retinal Degeneration’’ filed
September 11, 2020 (E–227–2017–PCT–
02); and U.S. and foreign patent
applications claiming priority to the
aforementioned applications.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to rights to
develop, make use and sell, a direct
ocular-administered formulation of
metformin for use as therapeutics to
treat retinal degenerative diseases in
human.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
Metformin administration to Retinal
Pigment Epithelium (‘‘RPE’’) cells
derived from age-related macular
degeneration patients and to RPE cells
derived from Stargart’s-patients shows
reduced accumulations of disease
associated retinal deposits, suggesting
clinical treatment value for metformin
in retinal degenerative diseases.
Metformin is FDA approved for the
treatment of diabetes. No formulation of
metformin is available for direct ocular
use. Development of a direct ocular
delivery metformin formulation could
provide improved treatment effects for
retinal degenerative diseases, without
major systemic side effects.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: October 15, 2020.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2020–23386 Filed 10–21–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\22OCN1.SGM
22OCN1
Federal Register / Vol. 85, No. 205 / Thursday, October 22, 2020 / Notices
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
Research Committee, Microbiology and
Infectious Diseases Research Committee
(MID).
Date: February 24–25, 2021.
Time: 10:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Amir E. Zeituni, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G51, Bethesda, MD
20892–9834, 301–496–2550, amir.zeituni@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–23368 Filed 10–21–20; 8:45 am]
Name of Committee: National Institute on
Drug Abuse Initial Review Group;
Medication Development Research
Subcommittee.
Date: November 5, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 3WFN, 9th Floor, MSC
6021, 301 North Stonestreet Avenue,
Bethesda, MD 20892, 301–827–5833,
ivan.navarro@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: October 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–23371 Filed 10–21–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
17:35 Oct 21, 2020
Jkt 253001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Interventions and Mechanisms for
Addiction.
Date: November 18, 2020.
Time: 12:00 p.m. to 5:00 p.m.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
67361
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marc Boulay, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
MSC 7808, Bethesda, MD 20892 (301) 300–
6541, boulaymg@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Medical Imaging.
Date: November 19–20, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Leonid V. Tsap, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5128,
MSC 7854, Bethesda, MD 20892, (301) 435–
2507, tsapl@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Infectious
Disease and Microbiology Fellowship Panel
II.
Date: November 19, 2020.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tamara Lyn McNealy,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3188,
Bethesda, MD 20892, 301–827–2372,
tamara.mcnealy@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Biochemistry and Biophysics of
Biological Macromolecules.
Date: November 19–20, 2020.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sudha Veeraraghavan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4166,
MSC 7846, Bethesda, MD 20892, (301) 435–
1504, sudha.veeraraghavan@nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group, HIV
Immunopathogenesis and Vaccine
Development Study Section.
Date: November 19–20, 2020.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Shiv A. Prasad, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
E:\FR\FM\22OCN1.SGM
22OCN1
]]>Agencies
[Federal Register Volume 85, Number 205 (Thursday, October 22, 2020)]
[Notices]
[Pages 67360-67361]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-23368]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections
[[Page 67361]]
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant
applications and the discussions could disclose confidential trade
secrets or commercial property such as patentable material, and
personal information concerning individuals associated with the grant
applications, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Microbiology, Infectious Diseases and AIDS
Initial Review Group; Microbiology and Infectious Diseases Research
Committee, Microbiology and Infectious Diseases Research Committee
(MID).
Date: February 24-25, 2021.
Time: 10:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Amir E. Zeituni, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G51,
Bethesda, MD 20892-9834, 301-496-2550, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 16, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-23368 Filed 10-21-20; 8:45 am]
BILLING CODE 4140-01-P
